• Mendus reported initial CADENCE and VITAL-CML trial results indicating vididencel improved immune competence in acute myeloid leukemia and chronic myeloid leukemia.
• VITAL-CML showed no sustained molecular disease improvement yet; longer follow-up is needed to assess treatment effects.
• CADENCE's first disease-progression readout is expected in the first half of 2027; VITAL-CML topline data are due in mid-2027.
• CADENCE results will be presented at the Australasian Leukaemia and Lymphoma Group scientific meeting, held November 10-13, 2026.
• VITAL-CML findings will be presented at the American Society of Hematology conference on December 13, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mendus AB (publ) published the original content used to generate this news brief on November 11, 2026, and is solely responsible for the information contained therein.